SCHEMBL10310587

SCHEMBL10310587

O=CCCCOCCC=O

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 0.50
TSHR P16473 2/20 0.41
MAPT P10636 1/20 0.34
FAAH O00519 2/20 0.33
TRPV1 Q8NER1 2/20 0.33
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545092 0.94 HIF1A (0.56) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL431901 0.91 HIF1A (0.53) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL127719 0.91 HIF1A (0.53) HIF1ATSHRMAPTFAAHTRPV1
SCHEMBL3955608 0.87
SCHEMBL23130636 0.84 HIF1A (0.41) HIF1ATSHRALDH1A1
SCHEMBL17613231 0.84 HIF1A (0.41) HIF1ATSHRALDH1A1
SCHEMBL18768831 0.84 HIF1A (0.41) HIF1ATSHRALDH1A1
SCHEMBL17613220 0.84 HIF1A (0.41) HIF1ATSHRALDH1A1
SCHEMBL11990606 0.84 HIF1A (0.41) HIF1ATSHRALDH1A1
SCHEMBL302670 0.82 TSHR (0.50) HIF1ATSHRMAPTFAAHTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER NEKTAR THERAPEUTICS 2017-02-09 US disclosed
US-9446139-B2 Polymer-based compositions and conjugates of HIV entry inhibitors NEKTAR THERAPEUTICS (US) 2016-09-20 US disclosed
US-20160175402-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES NEKTAR THERAPEUTICS 2016-06-23 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-8889831-B2 Unit dosage forms of pharmaceutical compositions comprising a polymer-factor VIII polypeptide conjugate NEKTAR THERAPEUTICS (US) 2014-11-18 US disclosed
US-8636994-B2 Polymer-based compositions and conjugates of antimicrobial agents NEKTAR THERAPEUTICS (US) 2014-01-28 US disclosed
US-8519102-B2 Polymer Factor VIII moiety conjugates NEKTAR THERAPEUTICS (US) 2013-08-27 US disclosed
US-20130195839-A1 Polymer-Based Compositions and Conjugates of Antimicrobial Agents NAKTAR THERAPEUTICS (US) 2013-08-01 US disclosed
US-8420068-B2 Polymer-based compositions and conjugates of antimicrobial agents NEKTAR THERAPEUTICS (US) 2013-04-16 US disclosed
US-20110171165-A1 POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES NEKTAR THERAPEUTICS 2011-07-14 US disclosed
US-20110171160-A1 POLYMER CONJUGATES OF KISS1 PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed
US-20110171161-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed
US-20110171163-A1 POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed
US-20110171164-A1 POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed
US-20110165113-A1 POLYMER CONJUGATES OF V681-LIKE PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed
US-20110165112-A1 POLYMER CONJUGATES OF C-PEPTIDES NEKTAR THERAPEUTICS (US) 2011-07-07 US disclosed
US-20110135623-A1 Conjugates of a Cholinesterase Moiety and a Polymer NEKTAR THERAPEUTICS (US) 2011-06-09 US disclosed
US-20100130684-A1 POLYMER FACTOR IX MOIETY CONJUGATES NEKTAR THERAPEUTICS (US) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110171160-A1 POLYMER CONJUGATES OF KISS1 PEPTIDES KISS1R, PROKR1, NGLY1 HIF1A 1549/4885TSHR 3332/4885MAPT 1096/4885
US-20110135623-A1 Conjugates of a Cholinesterase Moiety and a Polymer BCHE, ACHE, DNPEP HIF1A 4183/4885TSHR 2764/4885MAPT 494/4885
US-20110171163-A1 POLYMER CONJUGATES OF ZICONOTIDE PEPTIDES NGLY1, VIP, IAPP HIF1A 3105/4885TSHR 1342/4885MAPT 810/4885
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP HIF1A 2174/4885TSHR 2749/4885MAPT 405/4885
US-20130195839-A1 Polymer-Based Compositions and Conjugates of Antimicrobial Agents DDOST, CLSPN, DAD1 HIF1A 2570/4885TSHR 4618/4885MAPT 1482/4885
US-20110165112-A1 POLYMER CONJUGATES OF C-PEPTIDES IAPP, GCG, INSR HIF1A 2393/4885TSHR 2225/4885MAPT 2124/4885
US-20100130684-A1 POLYMER FACTOR IX MOIETY CONJUGATES F9, F13A1, F8 HIF1A 1175/4885TSHR 2747/4885MAPT 2188/4885
US-20110171161-A1 POLYMER CONJUGATES OF PROTEGRIN PEPTIDES PSMG3, PSMB11, PSMC5 HIF1A 3065/4885TSHR 3722/4885MAPT 860/4885
US-20160175402-A1 POLYMER-FACTOR VIII MOIETY CONJUGATES F8, F9, F13B HIF1A 1195/4885TSHR 3463/4885MAPT 2860/4885
US-20110166063-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP HIF1A 2174/4885TSHR 2749/4885MAPT 405/4885
US-20110165113-A1 POLYMER CONJUGATES OF V681-LIKE PEPTIDES NGLY1, VIP, DNPEP HIF1A 3383/4885TSHR 2797/4885MAPT 1166/4885
US-20110171165-A1 POLYMER CONJUGATES OF OPIOID GROWTH FACTOR PEPTIDES OGFR, OGFRL1, OPRL1 HIF1A 339/4885TSHR 1303/4885MAPT 821/4885
US-20110171164-A1 POLYMER CONJUGATES OF GLP-2-LIKE PEPTIDES IAPP, GLP1R, GIPR HIF1A 3043/4885TSHR 1433/4885MAPT 1470/4885
US-20170035898-A1 CONJUGATES OF AN IL-15 MOIETY AND A POLYMER IL15, IL15RA, IL2 HIF1A 2076/4885TSHR 2956/4885MAPT 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.